Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer.

CONCLUSION: FOLFIRINOX is an option for the first-line treatment of patients with pancreatic cancer and good performance status. PMID: 33315355 [PubMed - as supplied by publisher]
Source: Turkish Journal of Medical Sciences - Category: General Medicine Tags: Turk J Med Sci Source Type: research